<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580801</url>
  </required_header>
  <id_info>
    <org_study_id>CR013714</org_study_id>
    <secondary_id>VX-950-TiDP24-C210</secondary_id>
    <nct_id>NCT00580801</nct_id>
    <nct_alias>NCT00614237</nct_alias>
  </id_info>
  <brief_title>An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection</brief_title>
  <official_title>A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 4 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tibotec BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tibotec BVBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the activity and safety of telaprevir on Hepatitis C
      Virus (HCV) Genotype 4, alone or in combination with standard therapy, that is,
      pegylated-interferon-alfa-2a and ribavirin in treatment-naive (never been treated before with
      antiretroviral therapy) participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, partially-blind, randomized (study drug assigned by chance) and
      multiple-dose study to evaluate the activity and safety of telaprevir on HCV early viral
      kinetics in treatment-naive participants who are chronically infected with HCV Genotype 4.
      The study consists of 4 parts: Screening period (6-week); Investigational Treatment period
      (consisting of 2-week treatment with telaprevir or telaprevir+standard treatment or placebo);
      Standard Treatment period (consists of 46 or 48-week standard treatment); and Follow-up
      period (24-week). The activity of telaprevir will be evaluated by early viral kinetic
      parameters along with viral response and pharmacokinetic assessments during the
      investigational treatment phase. Participants' safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>The plasma HCV RNA levels were used to assess the antiviral activity which included viral response as either undetectable HCV RNA (that is no HCV target was detected in the plasma sample) or less than 25 International unit per milliliter (IU/mL) of HCV RNA (that is Plasma sample contained HCV RNA at a concentration below the limit of quantification [LLOQ=25 IU/mL] of the viral load assay). Plasma HCV RNA levels were measured using the COBAS TaqMan HCV test Version 2.0. This assay used real-time reverse transcription-polymerase chain reaction (RT-PCR) methodology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Response (Undetectable HCV RNA)</measure>
    <time_frame>Day 15 up to EOT (Week 48/50 or early discontinuation)</time_frame>
    <description>Viral response was either defined as having undetectable HCV RNA (that is, no HCV RNA was detected in the participants' plasma samples) or less than 25 IU/mL HCV RNA from Day 15 up to end of treatment (EOT), that is Week 48/50 or early discontinuation. In Week x/y, where, x represents time frame for Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin and Placebo+Pegylated-interferon-alfa-2a+Ribavirin and; y represents time frame for Telaprevir and Pegylated-interferon-alfa-2a+Ribavirin treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to First Viral Response (Undetectable HCV RNA)</measure>
    <time_frame>Up to Week 48/50</time_frame>
    <description>Time to first viral response (Undetectable HCV RNA) is defined as the number of days since the start of study medication until first time negative HCV RNA level that is less than 25 IU/mL was detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Viral Breakthrough (Detectable HCV RNA)</measure>
    <time_frame>Day 8, Day 12, Day 15, Week 24/26 and Week 36/38</time_frame>
    <description>Viral breakthrough was defined as having a confirmed increase greater than 1 log 10 in HCV RNA level from the lowest level reached, or a confirmed level of HCV RNA greater than 100 IU/mL in participants whose HCV RNA had previously become undetectable [less than 25 IU/mL]). In Week x/y, where, x represents time frame for Telaprevir+pegylated-interferon-alfa-2a+Ribavirin and Placebo+pegylated-interferon-alfa-2a+Ribavirin and y represents time frame for Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Viral Response (SVR)</measure>
    <time_frame>Week 12 and 24 after the last dose of study medication</time_frame>
    <description>Sustained viral response was defined as having undetectable HCV RNA at EOT (Week 48/50 or early discontinuation) and no confirmed detectable HCV RNA levels between EOT and 12 weeks (SVR12) and 24 weeks (SVR24) after the last dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Relapse</measure>
    <time_frame>Week 24 after EOT (Week 48/50 or early discontinuation)</time_frame>
    <description>Relapse was defined as having confirmed detectable HCV RNA during the 24-week follow-up period in participants who had undetectable HCV RNA at EOT (Week 48/50 or early discontinuation). Participants who dropped out between 24-week follow-up after EOT were not evaluated for relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve (AUC)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
    <description>The AUC is a measure of the serum concentration-time curve, calculated by the lin-up/log-down method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Telaprevir</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
    <description>The Cmax is the maximum observed serum concentration, which was measured at Day 1 and 15 for telaprevir and then pegylated-interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated-interferon-alfa-2a+Ribavirin (test).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Dose Serum Concentration (C[0h]) of Telaprevir</measure>
    <time_frame>0 hour (pre-dose) at Day 15</time_frame>
    <description>The C(0h) is the pre-dose serum concentration of telaprevir and then pegylated-interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated-interferon-alfa-2a+Ribavirin (test).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Telaprevir on Day 15</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 15</time_frame>
    <description>The Cmin is the minimum serum concentration between 0 hour and τ (τ=dosing interval) of telaprevir and then pegylated-interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated-interferon-alfa-2a+Ribavirin (test). Cmin on Day 15 is reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
    <description>The tmax is the time to reach maximum observed serum concentration of telaprevir and then pegylated-interferon-alfa-2a+Ribavirin (reference) and pegylated-interferon-alfa-2a+Ribavirin (test).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Steady-State Serum Concentration (Css,av) of Telaprevir</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
    <description>The Average steady-state serum concentration (Css,av) was calculated by AUC/τ at steady-state (τ=dosing interval) of telaprevir and then pegylated-interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated-interferon-alfa-2a+Ribavirin (test).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.</description>
    <arm_group_label>Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_label>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated-interferon-alfa-2a</intervention_name>
    <description>Pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.</description>
    <arm_group_label>Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_label>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_label>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.</description>
    <arm_group_label>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.</description>
    <arm_group_label>Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_label>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
    <arm_group_label>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Participant has chronic Genotype 4 Hepatitis C infection

          -  Plasma hepatitis C virus (HCV) ribonucleic acid (RNA) level greater than 10,000
             International unit per milliliter (IU/mL) at Screening

          -  Participant never received treatment for HCV

          -  Participant was to be in good health (besides HCV infection), in the opinion of the
             Investigator, judged on the basis of medical history and physical examination
             (including vital signs and screening electrocardiogram [ECG]), with any chronic
             medical conditions under stable medical control

          -  Participant had to be willing to refrain from the concomitant use of any medications
             or substances Exclusion Criteria: - Participants with history or evidence of cirrhosis
             or history of suspicion of alcohol, barbiturate, or amphetamine recreational or
             narcotic drug use, which in the Investigator's opinion would compromise the
             participant's safety and/or compliance with study procedures

          -  Participant has human immunodeficiency virus (HIV) or hepatitis B virus (HBV)
             co-infection

          -  Female participants who are pregnant, or planning to become pregnant, or
             breastfeeding, and partners of female participants who are pregnant or breastfeeding

          -  Participant has hypersensitivity to tartrazine

          -  Participant had participated in any clinical trial for an investigational drug within
             90 days before drug administration or participated in more than 2 drug studies in the
             last 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tibotec-Virco Virology BVBA Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Tibotec BVBA</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <results_first_submitted>March 7, 2013</results_first_submitted>
  <results_first_submitted_qc>June 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2013</results_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Telaprevir</keyword>
  <keyword>Pegylated-interferon-alfa-2a</keyword>
  <keyword>Pegasys</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Copegus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
        </group>
        <group group_id="P2">
          <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
        </group>
        <group group_id="P3">
          <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reached a virologic endpoint</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
        </group>
        <group group_id="B2">
          <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
        </group>
        <group group_id="B3">
          <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="36" upper_limit="61"/>
                    <measurement group_id="B2" value="41" lower_limit="28" upper_limit="52"/>
                    <measurement group_id="B3" value="46" lower_limit="30" upper_limit="56"/>
                    <measurement group_id="B4" value="45.5" lower_limit="28" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All Participants enrolled were from France.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15</title>
        <description>The plasma HCV RNA levels were used to assess the antiviral activity which included viral response as either undetectable HCV RNA (that is no HCV target was detected in the plasma sample) or less than 25 International unit per milliliter (IU/mL) of HCV RNA (that is Plasma sample contained HCV RNA at a concentration below the limit of quantification [LLOQ=25 IU/mL] of the viral load assay). Plasma HCV RNA levels were measured using the COBAS TaqMan HCV test Version 2.0. This assay used real-time reverse transcription-polymerase chain reaction (RT-PCR) methodology.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15</title>
          <description>The plasma HCV RNA levels were used to assess the antiviral activity which included viral response as either undetectable HCV RNA (that is no HCV target was detected in the plasma sample) or less than 25 International unit per milliliter (IU/mL) of HCV RNA (that is Plasma sample contained HCV RNA at a concentration below the limit of quantification [LLOQ=25 IU/mL] of the viral load assay). Plasma HCV RNA levels were measured using the COBAS TaqMan HCV test Version 2.0. This assay used real-time reverse transcription-polymerase chain reaction (RT-PCR) methodology.</description>
          <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
          <units>log 10 IU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HCV RNA levels: Baseline (n=8,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" lower_limit="5.2" upper_limit="6.5"/>
                    <measurement group_id="O2" value="6.16" lower_limit="5.4" upper_limit="6.8"/>
                    <measurement group_id="O3" value="5.88" lower_limit="5.0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV RNA levels: Change at Day 15 (n=7,8,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" lower_limit="-2.9" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-4.32" lower_limit="-5.2" upper_limit="0.0"/>
                    <measurement group_id="O3" value="-1.58" lower_limit="-4.0" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Viral Response (Undetectable HCV RNA)</title>
        <description>Viral response was either defined as having undetectable HCV RNA (that is, no HCV RNA was detected in the participants’ plasma samples) or less than 25 IU/mL HCV RNA from Day 15 up to end of treatment (EOT), that is Week 48/50 or early discontinuation. In Week x/y, where, x represents time frame for Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin and Placebo+Pegylated-interferon-alfa-2a+Ribavirin and; y represents time frame for Telaprevir and Pegylated-interferon-alfa-2a+Ribavirin treatment group.</description>
        <time_frame>Day 15 up to EOT (Week 48/50 or early discontinuation)</time_frame>
        <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Response (Undetectable HCV RNA)</title>
          <description>Viral response was either defined as having undetectable HCV RNA (that is, no HCV RNA was detected in the participants’ plasma samples) or less than 25 IU/mL HCV RNA from Day 15 up to end of treatment (EOT), that is Week 48/50 or early discontinuation. In Week x/y, where, x represents time frame for Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin and Placebo+Pegylated-interferon-alfa-2a+Ribavirin and; y represents time frame for Telaprevir and Pegylated-interferon-alfa-2a+Ribavirin treatment group.</description>
          <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point for each arm group respectively.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=7, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4/6 (n=7, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12/14 (n=7, 8, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/26 (n=6, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/38 (n=6, 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/50 (n=4, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOT (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to First Viral Response (Undetectable HCV RNA)</title>
        <description>Time to first viral response (Undetectable HCV RNA) is defined as the number of days since the start of study medication until first time negative HCV RNA level that is less than 25 IU/mL was detected.</description>
        <time_frame>Up to Week 48/50</time_frame>
        <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to First Viral Response (Undetectable HCV RNA)</title>
          <description>Time to first viral response (Undetectable HCV RNA) is defined as the number of days since the start of study medication until first time negative HCV RNA level that is less than 25 IU/mL was detected.</description>
          <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="44" upper_limit="100"/>
                    <measurement group_id="O2" value="85.50" lower_limit="29" upper_limit="171"/>
                    <measurement group_id="O3" value="128" lower_limit="86" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Viral Breakthrough (Detectable HCV RNA)</title>
        <description>Viral breakthrough was defined as having a confirmed increase greater than 1 log 10 in HCV RNA level from the lowest level reached, or a confirmed level of HCV RNA greater than 100 IU/mL in participants whose HCV RNA had previously become undetectable [less than 25 IU/mL]). In Week x/y, where, x represents time frame for Telaprevir+pegylated-interferon-alfa-2a+Ribavirin and Placebo+pegylated-interferon-alfa-2a+Ribavirin and y represents time frame for Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin treatment group.</description>
        <time_frame>Day 8, Day 12, Day 15, Week 24/26 and Week 36/38</time_frame>
        <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Viral Breakthrough (Detectable HCV RNA)</title>
          <description>Viral breakthrough was defined as having a confirmed increase greater than 1 log 10 in HCV RNA level from the lowest level reached, or a confirmed level of HCV RNA greater than 100 IU/mL in participants whose HCV RNA had previously become undetectable [less than 25 IU/mL]). In Week x/y, where, x represents time frame for Telaprevir+pegylated-interferon-alfa-2a+Ribavirin and Placebo+pegylated-interferon-alfa-2a+Ribavirin and y represents time frame for Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin treatment group.</description>
          <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/38</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Viral Response (SVR)</title>
        <description>Sustained viral response was defined as having undetectable HCV RNA at EOT (Week 48/50 or early discontinuation) and no confirmed detectable HCV RNA levels between EOT and 12 weeks (SVR12) and 24 weeks (SVR24) after the last dose of study medication.</description>
        <time_frame>Week 12 and 24 after the last dose of study medication</time_frame>
        <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Viral Response (SVR)</title>
          <description>Sustained viral response was defined as having undetectable HCV RNA at EOT (Week 48/50 or early discontinuation) and no confirmed detectable HCV RNA levels between EOT and 12 weeks (SVR12) and 24 weeks (SVR24) after the last dose of study medication.</description>
          <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Relapse</title>
        <description>Relapse was defined as having confirmed detectable HCV RNA during the 24-week follow-up period in participants who had undetectable HCV RNA at EOT (Week 48/50 or early discontinuation). Participants who dropped out between 24-week follow-up after EOT were not evaluated for relapse.</description>
        <time_frame>Week 24 after EOT (Week 48/50 or early discontinuation)</time_frame>
        <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
          <group group_id="O3">
            <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Relapse</title>
          <description>Relapse was defined as having confirmed detectable HCV RNA during the 24-week follow-up period in participants who had undetectable HCV RNA at EOT (Week 48/50 or early discontinuation). Participants who dropped out between 24-week follow-up after EOT were not evaluated for relapse.</description>
          <population>Full analysis included all randomized participants who received at least one dose of the telaprevir or placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-Time Curve (AUC)</title>
        <description>The AUC is a measure of the serum concentration-time curve, calculated by the lin-up/log-down method.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
        <population>Intent-to-treat (ITT) population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;n&quot; signifies number of participants with data for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-Time Curve (AUC)</title>
          <description>The AUC is a measure of the serum concentration-time curve, calculated by the lin-up/log-down method.</description>
          <population>Intent-to-treat (ITT) population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;n&quot; signifies number of participants with data for this measure at the specified time point for each arm group respectively.</population>
          <units>nanogram*hour/milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC : Day 1 (n=8, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6702" spread="3284"/>
                    <measurement group_id="O2" value="7467" spread="4684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC : Day 15 (n=7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17120" spread="3599"/>
                    <measurement group_id="O2" value="23320" spread="7065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least square mean ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.78</ci_upper_limit>
            <estimate_desc>Day 1: The least square (LS) means of the primary parameters for the test and the reference groups were estimated with a linear mixed effects model controlling for treatment group as fixed effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least square mean ratio</param_type>
            <param_value>1.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>Day 15: The LS means of the primary parameters for the test and the reference groups were estimated with a linear mixed effects model controlling for treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax) of Telaprevir</title>
        <description>The Cmax is the maximum observed serum concentration, which was measured at Day 1 and 15 for telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test).</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
        <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;n&quot; signifies number of participants with data for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax) of Telaprevir</title>
          <description>The Cmax is the maximum observed serum concentration, which was measured at Day 1 and 15 for telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test).</description>
          <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;n&quot; signifies number of participants with data for this measure at the specified time point for each arm group respectively.</population>
          <units>Nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax: Day 1 (n=8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1598" spread="803.1"/>
                    <measurement group_id="O2" value="1709" spread="1017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: Day 15 (n=7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2733" spread="554.9"/>
                    <measurement group_id="O2" value="3669" spread="1017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least square mean ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>Day 1: The LS means of the primary parameters for the test and the reference groups were estimated with a linear mixed effects model controlling for treatment group as fixed effects.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least square mean ratio</param_type>
            <param_value>1.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>Day 15: The LS means of the primary parameters for the test and the reference groups were estimated with a linear mixed effects model controlling for treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Dose Serum Concentration (C[0h]) of Telaprevir</title>
        <description>The C(0h) is the pre-dose serum concentration of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test).</description>
        <time_frame>0 hour (pre-dose) at Day 15</time_frame>
        <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Dose Serum Concentration (C[0h]) of Telaprevir</title>
          <description>The C(0h) is the pre-dose serum concentration of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test).</description>
          <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
          <units>Nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1873" spread="376.6"/>
                    <measurement group_id="O2" value="2806" spread="1056.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least square mean ratio</param_type>
            <param_value>1.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
            <estimate_desc>Day 15: The LS means of the primary parameters for the test and the reference groups were estimated with a linear mixed effects model controlling for treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Serum Concentration (Cmin) of Telaprevir on Day 15</title>
        <description>The Cmin is the minimum serum concentration between 0 hour and τ (τ=dosing interval) of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test). Cmin on Day 15 is reported here.</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 15</time_frame>
        <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Serum Concentration (Cmin) of Telaprevir on Day 15</title>
          <description>The Cmin is the minimum serum concentration between 0 hour and τ (τ=dosing interval) of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test). Cmin on Day 15 is reported here.</description>
          <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
          <units>Nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1639" spread="447.7"/>
                    <measurement group_id="O2" value="2100" spread="796.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least square mean ratio</param_type>
            <param_value>1.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>Day 15: The LS means of the primary parameters for the test and the reference groups were estimated with a linear mixed effects model controlling for treatment group as fixed effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir</title>
        <description>The tmax is the time to reach maximum observed serum concentration of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and pegylated–interferon-alfa-2a+Ribavirin (test).</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
        <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;n&quot; signifies number of participants with data for this measure at the specified time point for each arm group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir</title>
          <description>The tmax is the time to reach maximum observed serum concentration of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and pegylated–interferon-alfa-2a+Ribavirin (test).</description>
          <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;n&quot; signifies number of participants with data for this measure at the specified time point for each arm group respectively.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>tmax: Day 1 (n=8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="447.7" lower_limit="3.00" upper_limit="5.97"/>
                    <measurement group_id="O2" value="4.00" spread="796.3" lower_limit="3.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tmax: Day 15 (n=7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" lower_limit="0.00" upper_limit="4.08"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.92" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Steady-State Serum Concentration (Css,av) of Telaprevir</title>
        <description>The Average steady-state serum concentration (Css,av) was calculated by AUC/τ at steady-state (τ=dosing interval) of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test).</description>
        <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 6 and 8 hours post-dose on Day 1 and 15</time_frame>
        <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
          </group>
          <group group_id="O2">
            <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
            <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Steady-State Serum Concentration (Css,av) of Telaprevir</title>
          <description>The Average steady-state serum concentration (Css,av) was calculated by AUC/τ at steady-state (τ=dosing interval) of telaprevir and then pegylated–interferon-alfa-2a+Ribavirin (reference) and telaprevir+pegylated–interferon-alfa-2a+Ribavirin (test).</description>
          <population>ITT population included any randomized participant who received at least 1 dose of telaprevir/placebo. &quot;N&quot; signifies those participants who were evaluated for this measure.</population>
          <units>Nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2141" spread="438.5"/>
                    <measurement group_id="O2" value="2896" spread="842.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telaprevir and Then Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Telaprevir 750 milligram (mg) tablet was administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 2 to 50.</description>
        </group>
        <group group_id="E2">
          <title>Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Telaprevir 750 mg tablet was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
        </group>
        <group group_id="E3">
          <title>Placebo+Pegylated-interferon-alfa-2a+Ribavirin</title>
          <description>Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily) was administered from Week 1 to 48.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator agrees that before he/she publishes any results of this trial he/she shall allow at least 45 days for the Sponsor to review the pre-publication manuscript prior to submission of the manuscript to the Publisher. In accordance with generally recognized principles of scientific collaboration, co-authorship with any company personnel will be discussed and mutually agreed upon before submission of the manuscript to the Publisher.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader</name_or_title>
      <organization>Janssen Research &amp; Development, LLC, Titusville, NJ</organization>
      <phone>609-730-3174</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

